Document is current
Any future updates will be listed below
-
Authors
Dulobdas, Vaishali https://orcid.org/0009-0007-6377-0829
Kirkwood, Amy A.
Serpenti, Fabio
Gautama, Brijesh https://orcid.org/0009-0008-3299-3744
Panopoulou, Aikaterini
Mathew, Amrith https://orcid.org/0000-0002-5826-6675
Gabriel, Sumantha
Malladi, Ram
Pealing, Jessica
Bonney, Denise
Nicholson, Emma https://orcid.org/0000-0002-6439-0795
Besley, Caroline
Ghorashian, Sara
Kuhnl, Andrea
Davies, Elizabeth
Chappell, Jackie
Black, Anne
Menne, Tobias
O’Reilly, Maeve A.
Sanderson, Robin
Chaganti, Sridhar https://orcid.org/0009-0002-3881-5654
- License Information
-
More Information
Article History
Received: 21 August 2024
Revised: 13 January 2025
Accepted: 31 January 2025
First Online: 4 March 2025
Competing interests
: VD has received meeting attendance support from Kite-Gilead and Abbvie and honoraria from Abbvie. AAK has received honoraria from Kite-Gilead and Janssen. BG has received honoraria from Kite-Gilead and travel support from Kite-Gilead and Janssen. ED has received honoraria from Kite-Gilead. AP has received meeting attendance support from Kite-Gilead. SG has received honoraria from Accord, Janssen, Pfizer, Abbvie and Kite-Gilead. RM has received honoraria from Novartis and Kite-Gilead and travel support from Kite-Gilead. EN has received honoraria from Novartis, BMS-Celgene and Kite-Gilead and travel support from Kite-Gilead and research grant from Kite-Gilead. CB has received honoraria from Kite-Gilead, Novartis, Janssen and Takeda and travel support from Kite-Gilead and Janssen. SG has received honoraria from Novartis and holds patents and Royalties with UCLB. AK has received honoraria from Kite/Gilead, Roche, BMS, Abbvie and travel sponsorship from Kite/Gilead and AstraZeneca. JC has received honoraria from Abbvie, Miltenyi Biotec and Vertex. AB has received honoraria from Pierre fabre and Kite-Gilead. TM has received honoraria from Kite-Gilead, Amgen, Novartis, Pfizer, Celgene-BMS, Daiichi Sankyo, Atara, Roche, Janssen; Research Funding from Janssen, AstraZeneca, Novartis; Travel grants from Amgen, Jazz, Pfizer, Bayer, Kyowa Kirin, Celgene-BMS, Kite-Gilead, Janssen, Takeda; Speaker fee from Kite/Gilead, Takeda, Janssen, F. Hoffmann-La Roche Ltd, Servier, Novartis, Celgene/BMS, Pfizer, Incyte; Divested equity in a private or publicly-traded company in the past 24 months, Kite/Gilead, Amgen, Novartis, Pfizer, Celgene/BMS, Daiichi Sankyo, Atara, F. Hoffmann-La Roche Ltd, Janssen, BMS, CTI BioPharma, Blueprint Medicines, Sanofi-Aventis, Spark Therapeutics. M O’R has received honoraria from Autolus Janssen, Kite-Gilead and Novartis, advisory board for Kite-Gilead and Autolus and travel grant from Kite-Gilead. RS has received honoraria from Novartis, Kite-Gilead, AstraZeneca and Abbvie and meeting attendance support from Kite-Gilead and AstraZeneca. SC has received honoraria from Takeda, Kite/Gilead, Incyte, AbbVie, Pierre Fabre: F. Hoffmann-La Roche Ltd, Atara Bio, Orion Pharma, Adicet Bio, Incyte, Novartis, Amgen, Sobi, Pierre Fabre, BMS-Celgene and Miltenyi Biotec and meeting attendance support from Takeda, Kite-Gilead, Abbvie, and Pierre Fabre. FS and AM have no competing interests.
: This retrospective study was part of a national service evaluation exercise on behalf of the NHS England OOS CAR T Clinical Panel, not requiring separate ethics approval. Patients were consented for deidentified or pseudo-anonymised data collection and sharing as per institutional protocols. The study was conducted in accordance with relevant guidelines and regulations.
